27
2022Salt
AGENCY STATEMENT
Salt is a strategic creative agency with a passion for health. We offer clear, joined-up thinking that creates positive change. We believe in taking an honest, original approach to any challenge, considering all aspects to develop bespoke and compelling results that work.

- Agency description
We offer clear, joined-up thinking that creates positive change. Nothing overcomplicated or unnecessary, just the fundamental elements developed into strong ideas and creative solutions that make a difference.
We believe in taking an honest, original approach to any challenge, considering all aspects to develop bespoke and compelling results that work.
We love a challenge – a problem that needs some proper thinking to find a good solution. We’re not afraid of constraints, they make us more creative. Now in our fifth year, we have established ourselves with a diverse and dynamic client base and a track record of innovative, effective work.
We will always develop ideas for the right reasons, ideas that get under the skin of the challenge and are designed to make a difference.
At the end of the day, we believe there is a creative opportunity in pretty much anything, as long as you’re willing to look for it.
- Contact details
- 201 Borough High Street London SE1 1JA
- 020 7971 1067
- hello@saltthinking.com
- https://saltthinking.com
- Key contact
- Kath Cotton
- Managing Director
- kath@saltthinking.com
- 020 7971 1067
- 2022 Agency Data
-
2021 awardsTotal staff10-24 staffBillings from UK creative healthcare workHealthcare staff10-24 staffTotal agency billingsAgency ageBetween 5 and 7 yearsSocial media footprintStatusINDEPENDENTApproximate percentage of advertising, branding, creative or design work in the UK healthcare market90-100%
- This information was supplied or confirmed by Salt. Bar charts are indicative only, with 100% being the maximum score allocated across all agencies. Billings from UK creative healthcare work are not a subset of total annual billings, and so may show a higher rating.
- Ranking factors contributing to agency score
- This chart shows the relative factors that contributed to the agency's overall ranking.
- Awards
- 2021 Communique Awards:
Finalist, Excellence in Patient Programmes, Fighting Failure: Reprioritising Heart Failure Care in the UK
PMEA 2021:
Winner, Excellence in Patient Education and Support, Fighting Failure: Reprioritising Heart Failure Care in the UK
PMEA 2021:
Winner, Excellence in New Product Introductions, Jazz Pharmaceuticals' EU Launch of Sunosi (solriamfetol) - This may contain additional awards supplied by Salt that were not included when generating this year’s T40 - please see methodology to find out which awards schemes were included.
COVID-19 Updates and Daily News
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Technical Sales Representative
- Highly competitive salary
Quick links
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- The state of pharma customer experience
- GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...